JP2019510805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510805A5 JP2019510805A5 JP2018553111A JP2018553111A JP2019510805A5 JP 2019510805 A5 JP2019510805 A5 JP 2019510805A5 JP 2018553111 A JP2018553111 A JP 2018553111A JP 2018553111 A JP2018553111 A JP 2018553111A JP 2019510805 A5 JP2019510805 A5 JP 2019510805A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery system
- hydrogen peroxide
- oral
- target location
- gastrointestinal tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 42
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- 229940088598 enzyme Drugs 0.000 claims 6
- 238000011065 in-situ storage Methods 0.000 claims 6
- 239000011859 microparticle Substances 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 102000006265 Dual Oxidases Human genes 0.000 claims 3
- 108010083068 Dual Oxidases Proteins 0.000 claims 3
- 102000004019 NADPH Oxidase 1 Human genes 0.000 claims 3
- 108090000424 NADPH Oxidase 1 Proteins 0.000 claims 3
- 239000002702 enteric coating Substances 0.000 claims 3
- 238000009505 enteric coating Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102100024391 Dual oxidase maturation factor 2 Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010015776 Glucose oxidase Proteins 0.000 claims 1
- 239000004366 Glucose oxidase Substances 0.000 claims 1
- 101001053276 Homo sapiens Dual oxidase maturation factor 2 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000003923 Protein Kinase C Human genes 0.000 claims 1
- 108090000315 Protein Kinase C Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940116332 glucose oxidase Drugs 0.000 claims 1
- 235000019420 glucose oxidase Nutrition 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605954 | 2016-04-07 | ||
| GB1605954.5 | 2016-04-07 | ||
| PCT/EP2017/058289 WO2017174744A1 (en) | 2016-04-07 | 2017-04-06 | Treatment of inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510805A JP2019510805A (ja) | 2019-04-18 |
| JP2019510805A5 true JP2019510805A5 (enExample) | 2020-05-21 |
Family
ID=58645001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553111A Pending JP2019510805A (ja) | 2016-04-07 | 2017-04-06 | 炎症性腸疾患の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10869834B2 (enExample) |
| EP (1) | EP3439619A1 (enExample) |
| JP (1) | JP2019510805A (enExample) |
| WO (1) | WO2017174744A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3915552A1 (en) * | 2015-06-01 | 2021-12-01 | Xeno Biosciences Inc. | Compositions for use in modulating the gut microbiota and managing weight |
| WO2018102469A1 (en) | 2016-11-30 | 2018-06-07 | Xeno Biosciences Inc. | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota |
| KR20220163450A (ko) | 2020-04-03 | 2022-12-09 | 엘폭시 세라퓨틱스 인코퍼레이티드 | 장 호기화 요법 |
| WO2022175262A1 (en) * | 2021-02-16 | 2022-08-25 | Dsm Ip Assets B.V. | Methods for reducing pathogenic e coli by selective feed additive intervention comprising enzymes such as muramidase |
| EP4398876A4 (en) | 2021-09-29 | 2025-07-23 | Lpoxy Therapeutics Inc | ENTERIC AEROBIZATION THERAPY |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US20100179646A1 (en) * | 2009-01-09 | 2010-07-15 | Rainbow Medical Ltd. | Glucose oxidase techniques |
| US8722040B2 (en) * | 2011-06-24 | 2014-05-13 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
| WO2013181331A2 (en) * | 2012-05-30 | 2013-12-05 | Ibh Ventures, Llc | Polyphenol-reactive oxygen species compositions and methods |
| US8716351B1 (en) * | 2012-12-23 | 2014-05-06 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms |
| WO2015192136A1 (en) * | 2014-06-13 | 2015-12-17 | Liveleaf, Inc. | Non-toxic agent for a broad-spectrum, bactericidal or bacteriostatic treatment of antibiotic-resistant bacteria in animals |
-
2017
- 2017-04-06 WO PCT/EP2017/058289 patent/WO2017174744A1/en not_active Ceased
- 2017-04-06 JP JP2018553111A patent/JP2019510805A/ja active Pending
- 2017-04-06 EP EP17720368.4A patent/EP3439619A1/en not_active Withdrawn
- 2017-04-06 US US16/091,312 patent/US10869834B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510805A5 (enExample) | ||
| JP2021113227A (ja) | リナクロチドの遅延放出組成物 | |
| US20220184222A1 (en) | Bicycle toxin conjugates and uses thereof | |
| Talaei et al. | Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies | |
| KR102198749B1 (ko) | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 | |
| ES2901122T3 (es) | Composición de liberación modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados | |
| BR112015026418B1 (pt) | Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina | |
| RU2008136208A (ru) | Композиции для эффектора плотных контактов | |
| Singh et al. | New generation smart drug delivery systems for rheumatoid arthritis | |
| JP2008519070A5 (enExample) | ||
| MD3684344T2 (ro) | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora | |
| RU2619869C2 (ru) | Композиция гидрокортизона с контролируемым высвобождением | |
| ES2716115T3 (es) | Una composición farmacéutica que contiene conbinaciones de nicotinamida y ácido 5-aminosalicílico para influir de forma beneficiosa en la microbiota intestinal y/o tratar la inflamación gastrointestinal | |
| JP2021152050A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| JP2024161048A (ja) | リナクロチドの改変または標的放出製剤 | |
| JP2022093472A (ja) | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 | |
| JP2013537221A (ja) | 改良された経口標的化薬物送達システム | |
| BR112020003375A2 (pt) | composições de amantadina, preparações das mesmas, e métodos de uso | |
| JP2009538919A (ja) | フェニレフリンのパルス化放出処方物および薬学的組成物 | |
| CN109152772A (zh) | 烟酰胺的口服药物组合物 | |
| JP2020510691A (ja) | 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物 | |
| CA2609618A1 (en) | Novel acetylsalicylic acid formulations | |
| Newton et al. | IBD–impact of colonic pH, onset of action and other factors in modern therapeutic approach | |
| KR20200121302A (ko) | 간세포성 암종의 치료를 위한 조합 요법 | |
| JP2003512311A (ja) | Ｃｎｓ介在性障害を治療するための持続放出製剤 |